Company intelligence / Profile preview
Nona Biosciences
- Ownership
- Private
- Development stage
- Other
Overview
Nona Biosciences has demonstrated robust antibody engineering capabilities with proprietary transgenic mouse platforms. Their technologies have enabled the generation of novel therapeutic candidates—such as the mesothelin-targeting ADC developed with Pfizer—which have shown promising preclinical results presented at AACR in April 2025. The company’s focus remains on accelerating antibody drug discovery from target validation through IND-enabling studies using both traditional wet-lab methods and advanced AI-driven approaches.
- Therapeutic areas
- OncologyMetabolic DisordersNeurology
- Modalities
- Fully human monoclonal antibodies (H2L2 format)Heavy chain only antibodies (HCAb format)Single domain antibodies / VH domainsBispecific/multispecific antibodiesCAR-T and cell therapiesADCs (antibody-drug conjugates)mRNA-based modalities
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Nona Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nona Biosciences.